β muricholic acid

Tauro-β-muricholic Acid sodium is a endogenous metabolite, is a competitive and reversible antagonist of farnesoid X receptor (FXR)(IC50 of 40 μM).

Tauro-β-muricholic acid (TβMCA), a trihydroxylated bile acid, acts as a competitive and reversible FXR antagonist (IC 50 = 40 μM) and exhibits antiapoptotic effects by inhibiting bile acid-induced hepatocellular apoptosis and preserving mitochondrial membrane potential [1] [2].

Tauro-α-muricholic acid (TαMCA) is an antagonist of the farnesoid X receptor (FXR; IC50 = 28 μM) and a taurine-conjugated form of the murine-specific primary bile acid α-muricholic acid . TαMCA is common in rodents but has also been found in small amounts in human serum.

ω-Muricholic acid (ω-MCA) is a murine-specific secondary bile acid.

β-Muricholic acid (β-MCA) is a murine-specific primary bile acid.[1],[2] Dietary administration of β-MCA reduces HMG-CoA reductase activity in liver microsomes from mice fed a high cholesterol and cholic acid diet.[3] Dietary administration of β-MCA also dissolves 100% of gallstones in a gallstone-susceptible mouse model of diet-induced cholesterol gallstones.[4]

Tauro-ω-muricholic acid sodium (TωMCA sodium) is an analogue of tauro-α-muricholic acid, a bile acid of hepatic origin. Tauro-ω-muricholic acid sodium can be used as a serum marker for early onset neonatal sepsis (EOS) and biliary stasis.

α-Muricholic acid is the most abundant primary bile acid in rodents.